← All candidates
75 insider filings on record.
75 filings on record.
MAZEMaze Therapeutics, Inc.
NasdaqGM · Healthcare · $1.34B
$24.23
-1.78% · Sep 15
75 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 44 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.34B
Float
36.8M
66% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
66.9
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
70 more transactions on Pro →Context
Wall St
$62.55 avg target
+158.1% vs today · 11 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 3 quarters beat
Q4 '25−$0.65 act+$0.04
Q3 '25−$0.66 act+$0.03
Q2 '25−$0.77 act+$0.39
Coverage
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?Motley Fool · 06-29Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And RiskSimply Wall St. · 06-13Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right NowInsider Monkey · 06-08Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?Motley Fool · 06-05
The file stays open
75 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice